In conclusion, our discovery that MTBR/R’-containing and related fragments are potent mediators of the synaptic plasticity-disrupting actions of patient-derived soluble synaptotoxic tau provides a biological basis for interpreting ongoing biomarker-based clinical trials in AD immunotherapy. This evidence concerns the gene MAPT and Alzheimer disease.